Skip to Content

Ondine Biomedical Inc Common Share VF5

Morningstar Rating
€0.06 0.00 (0.78%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VF5 is trading at a 38% premium.
Price
€0.06
Fair Value
€6.97
Uncertainty
Extreme
1-Star Price
€1.45
5-Star Price
€5.80
Economic Moat
Djtz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VF5 is a good fit for your portfolio.

Trading Information

Previous Close Price
€0.06
Day Range
€0.060.06
52-Week Range
€0.040.66
Bid/Ask
€0.00 / €0.00
Market Cap
€17.88 Mil
Volume/Avg
0 /

Key Statistics

Price/Earnings (Normalized)
Price/Sales
21.91
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
43

Valuation

Metric
VF5
Price/Earnings (Normalized)
Price/Book Value
4.37
Price/Sales
21.91
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
VF5
Quick Ratio
1.71
Current Ratio
2.34
Interest Coverage
−464.17
Quick Ratio
VF5

Profitability

Metric
VF5
Return on Assets (Normalized)
−101.11%
Return on Equity (Normalized)
−132.51%
Return on Invested Capital (Normalized)
−127.20%
Return on Assets
VF5
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
QdzblkxZxlwjl$124.1 Bil
Regeneron Pharmaceuticals Inc
REGN
YhftgnzfVckqc$114.2 Bil
Moderna Inc
MRNA
XlspdknnPww$53.7 Bil
argenx SE ADR
ARGX
GlylyjhcKnyb$23.0 Bil
BioNTech SE ADR
BNTX
QdmfnwfjkVppz$22.2 Bil
Alnylam Pharmaceuticals Inc
ALNY
QhmdvfrmTnykhtb$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
DdcgwvhSzqqfh$15.9 Bil
United Therapeutics Corp
UTHR
WlqhwqcmJktl$12.8 Bil
Incyte Corp
INCY
WwxxjnjcBpkccz$12.2 Bil
Royalty Pharma PLC Class A
RPRX
KxvlrdgbcPpjqbk$12.2 Bil

Sponsor Center